Downregulation of TMTC4 expression is associated with improved prognosis in sarcoma

Osteosarcoma is the most common bone tissue tumor. The expression of Transmembrane and Tetratricopeptide Repeat Containing 4 (TMTC4) in osteosarcoma has never been reported. Therefore, the purpose of this study is to study the significance of TMTC4 in the prognosis of sarcoma. Screening the expression level of downstream genes after interleukin-11 receptor alpha (IL11RA) knockout in osteosarcoma through Gene Expression Synthesis (GEO) database. Use The Cancer Genome Atlas (TCGA) database and cloud data to further analyze the expression level and influence of TMTC4 in sarcoma and subgroup analysis. PCR was used to detect the expression level of TMTC4 among human osteoblast hFOB1.19 and human Osteosarcoma cells MG-63, U2OS and Saos-2, and CCK-8 was used to detect cell proliferation levels. Through GSE191215 database, 11 down-regulated genes such as TMTC4 were screened. KM curve shows that sarcomas with low TMTC4 expression level can show higher survival rate. The results of enrichment analysis showed that the low expression level of TMTC4 might be related to IMMUNOREGULATORY and ANTIGEN_ ACTIVATES. Methylation analysis showed that the methylation level of TMTC4 was increased in sarcomas. In addition, the expression level of TMTC4 in the Osteosarcoma group (MG-63, U2OS, Saos-2) was significantly higher than in hFOB1.19 and inhibition of TMTC4 expression impedes Osteosarcoma cell proliferation. Our results show that TMTC4 is an important biomarker in patients with sarcoma, and its low expression level is related to the improvement of the prognosis of sarcoma.